Clinical Trial Update: Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF [Phase 3]

View source ↗

Summary

Phase 3 trial comparing momelotinib to best available therapy in anemic or thrombocytopenic patients with various subtypes of myelofibrosis; trial completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Best Available Therapy
• Momelotinib (momelotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) | Phase 3 | Status: COMPLETED | Results posted: 2023-05-23